NASDAQ:SNY - Sanofi Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$51.30
▲ +0.61 (1.20%)
1 month | 3 months | 12 months
Get New Sanofi Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $51.30.
Hold
The current consensus among 9 investment analysts is to hold stock in Sanofi. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/6/2021BarclaysReiterated RatingEqual WeightLow
i
2/10/2021Morgan StanleyReiterated RatingOverweightLow
i
1/19/2021UBS GroupReiterated RatingBuyLow
i
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageSellLow
i
1/8/2021Morgan StanleyReiterated RatingOverweightLow
i
11/3/2020Morgan StanleyReiterated RatingOverweightMedium
i
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
i
10/4/2020The Goldman Sachs GroupInitiated CoverageBuyMedium
i
9/29/2020Berenberg BankInitiated CoverageHoldLow
i
8/19/2020Stifel NicolausDowngradeBuy ➝ HoldLow
i
8/18/2020SVB LeerinkDowngradeMarket PerformLow
i
7/31/2020JPMorgan Chase & Co.Reiterated RatingOverweightMedium
i
6/9/2020Morgan StanleyReiterated RatingOverweightMedium
i
5/26/2020UBS GroupReiterated RatingBuyMedium
i
4/28/2020BarclaysReiterated RatingEqual WeightMedium
i
Rating by Emmanuel Papadakis at Barclays PLC
4/21/2020Morgan StanleyReiterated RatingOverweightMedium
i
3/17/2020BarclaysUpgradeUnderweight ➝ Equal WeightHigh
i
Rating by Emmanuel Papadakis at Barclays PLC
3/10/2020The Goldman Sachs GroupUpgradeNeutral ➝ BuyMedium
i
2/19/2020ArgusBoost Price TargetBuy$52.00 ➝ $56.00Low
i
2/11/2020SVB LeerinkInitiated CoverageMarket Perform$58.00Low
i
Rating by G. Porges at SVB Leerink LLC
2/7/2020DZ BankReiterated RatingNeutralLow
i
1/22/2020Liberum CapitalDowngradeBuy ➝ HoldLow
i
1/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
i
12/6/2019BarclaysDowngradeEqual Weight ➝ UnderweightLow
i
11/13/2019ArgusReiterated RatingBuy$50.00 ➝ $52.00Low
i
10/14/2019JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
9/23/2019GuggenheimUpgradeNeutral ➝ BuyLow
i
9/20/2019Morgan StanleyUpgradeEqual ➝ Equal WeightMedium
i
9/3/2019Sanford C. BernsteinInitiated CoverageOutperform$52.00Low
i
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
i
8/14/2019UBS GroupUpgradeNeutral ➝ BuyHigh
i
8/6/2019JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
2/28/2019HC WainwrightReiterated RatingBuyLow
i
1/14/2019JPMorgan Chase & Co.Reiterated RatingNeutralMedium
i
12/14/2018Morgan StanleyInitiated CoverageEqual WeightLow
i
12/11/2018Jefferies Financial GroupUpgradeHold ➝ BuyLow
i
12/4/2018JPMorgan Chase & Co.Reiterated RatingNeutralMedium
i
11/30/2018UBS GroupReiterated RatingNeutralLow
i
11/8/2018ArgusBoost Price TargetBuy ➝ Buy$48.00 ➝ $50.00Low
i
11/1/2018BarclaysUpgradeUnderweight ➝ Equal WeightLow
i
Rating by Emmanuel Papadakis at Barclays PLC
10/31/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
10/23/2018Wolfe ResearchInitiated CoverageMarket PerformLow
i
10/15/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
i
9/10/2018Bank of AmericaUpgradeNeutral ➝ Buy$55.00Medium
i
8/24/2018ArgusBoost Price TargetBuy ➝ Buy$46.00 ➝ $48.00Low
i
8/10/2018CitigroupUpgradeNeutral ➝ BuyHigh
i
8/1/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
8/1/2018BNP ParibasUpgradeNeutral ➝ OutperformLow
i
7/31/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
4/16/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
3/23/2018Liberum CapitalUpgradeHold ➝ BuyLow
i
3/12/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
2/8/2018Sanford C. BernsteinReiterated RatingMarket Perform$50.00 ➝ $45.00Low
i
1/23/2018BarclaysDowngradeEqual Weight ➝ UnderweightLow
i
1/15/2018UBS GroupReiterated RatingNeutralLow
i
1/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
1/2/2018Nord/LBReiterated RatingNeutralLow
i
12/27/2017Nord/LBReiterated RatingNeutralLow
i
12/18/2017CowenSet Price TargetHold$48.00Low
i
Rating by Steve Scala at Cowen Inc
12/14/2017JPMorgan Chase & Co.Reiterated RatingNeutralHigh
i
12/6/2017Bank of AmericaDowngradeBuy ➝ NeutralLow
i
12/1/2017Morgan StanleyDowngradeOverweight ➝ UnderweightLow
i
11/15/2017BarclaysUpgradeUnderweight ➝ Equal WeightN/A
i
9/15/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
Rating by Richard Vosser at JPMorgan Chase & Co.
9/1/2017ArgusReiterated RatingBuy$55.00Medium
i
8/1/2017CowenReiterated RatingMarket Perform$46.00 ➝ $52.00Low
i
6/9/2017ArgusBoost Price TargetBuy$50.00 ➝ $55.00Low
i
5/11/2017Berenberg BankDowngradeBuy ➝ HoldLow
i
4/20/2017JPMorgan Chase & Co.Reiterated RatingNeutralMedium
i
Rating by Richard Vosser at JPMorgan Chase & Co.
4/11/2017JPMorgan Chase & Co.UpgradeUnderperform ➝ NeutralMedium
i
4/6/2017ArgusInitiated CoverageBuy ➝ Buy$50.00Low
i
4/5/2017JPMorgan Chase & Co.Reiterated RatingSellLow
i
3/30/2017JPMorgan Chase & Co.Reiterated RatingSellLow
i
3/9/2017Liberum CapitalInitiated CoverageHold ➝ HoldLow
i
3/7/2017BarclaysInitiated CoverageUnderweightN/A
i
2/9/2017NatixisUpgradeNeutral ➝ BuyN/A
i
1/10/2017SVB LeerinkReiterated RatingOutperformN/A
i
1/8/2017The Goldman Sachs GroupReiterated RatingHoldN/A
i
Rating by Keyur Parekh at The Goldman Sachs Group, Inc.
11/29/2016Morgan StanleyUpgradeEqual Weight ➝ OverweightN/A
i
11/7/2016The Goldman Sachs GroupInitiated CoverageNeutralN/A
i
10/9/2016SVB LeerinkReiterated RatingBuyN/A
i
9/26/2016SVB LeerinkReiterated RatingBuyN/A
i
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/A
i
9/15/2016JPMorgan Chase & Co.Reiterated RatingUnderweightN/A
i
9/14/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
9/13/2016BNP ParibasUpgradeUnderperform ➝ NeutralN/A
i
9/8/2016Berenberg BankUpgradeHold ➝ BuyN/A
i
8/15/2016Berenberg BankReiterated RatingHold$93.00N/A
i
6/28/2016CitigroupReiterated RatingNeutralN/A
i
5/12/2016BarclaysUpgradeEqual Weight ➝ OverweightN/A
i
5/3/2016Bank of AmericaReiterated RatingBuy$58.00N/A
i
4/27/2016CitigroupReiterated RatingNeutralN/A
i
4/25/2016JPMorgan Chase & Co.Reiterated RatingSellN/A
i
(Data available from 4/17/2016 forward)
Sanofi logo
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Read More

Today's Range

Now: $51.30
$50.80
$51.48

50 Day Range

MA: $48.60
$45.46
$50.77

52 Week Range

Now: $51.30
$43.17
$55.00

Volume

958,078 shs

Average Volume

2,447,063 shs

Market Capitalization

$129.17 billion

P/E Ratio

21.92

Dividend Yield

2.33%

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Sanofi?

The following Wall Street sell-side analysts have issued stock ratings on Sanofi in the last twelve months: Barclays PLC, Berenberg Bank, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for SNY.

What is the current price target for Sanofi?

0 Wall Street analysts have set twelve-month price targets for Sanofi in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sanofi in the next year.
View the latest price targets for SNY.

What is the current consensus analyst rating for Sanofi?

Sanofi currently has 1 sell rating, 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SNY, but not buy more shares or sell existing shares.
View the latest ratings for SNY.

What other companies compete with Sanofi?

How do I contact Sanofi's investor relations team?

Sanofi's physical mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company's listed phone number is 33 1 53 77 40 00 and its investor relations email address is [email protected] The official website for Sanofi is www.sanofi.com.